Brian Stephenson Buys 5,000 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This trade represents a 11.99% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Sensei Biotherapeutics Stock Down 3.1%

Shares of NASDAQ FTH opened at $22.92 on Friday. Sensei Biotherapeutics, Inc. has a 12 month low of $6.32 and a 12 month high of $36.76. The stock has a market cap of $30.76 million, a PE ratio of -0.16 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective on the stock. Finally, HC Wainwright started coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.